Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
Status:
Completed
Trial end date:
1998-07-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Assess the clinical response of patients with refractory or recurrent brain neoplasms
treated with carmustine, streptozocin, and mercaptopurine.